Avacta Group PLC (GB:AVCT)
LSE:AVCT
Top Page
Avacta Group plc
(LSE:AVCT)
Select Model
Select Model
Rating:42Neutral
Price Target:
48.00 p
▼(-26.15% Downside)
Action:ReiteratedDate:12/19/25
Avacta Group plc's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock's valuation is unattractive due to negative earnings and no dividend yield.
Positive Factors
Platform & Target Coverage
Avacta's proprietary Affimer/pre|CISION platform, validated by Tempus showing FAP expression in 90% of solid tumors, supports a broad addressable oncology opportunity. This structural validation strengthens partner interest, licensing prospects and long-term pipeline utility across many tumor types.
Negative Factors
Weak Balance Sheet & Leverage
A deteriorating balance sheet with rising leverage and a weakened equity ratio constrains strategic flexibility. Higher indebtedness increases financing costs, elevates covenant and refinancing risk, and can force dilutive funding or scaled-back R&D, impairing long-term execution capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Target Coverage
Avacta's proprietary Affimer/pre|CISION platform, validated by Tempus showing FAP expression in 90% of solid tumors, supports a broad addressable oncology opportunity. This structural validation strengthens partner interest, licensing prospects and long-term pipeline utility across many tumor types.
Read all positive factors
Avacta Group plc (AVCT) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£285.19M
Dividend YieldN/A
Average Volume (3M)3.07M
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees154
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding440,415,500
10 Day Avg. Volume4,236,507
30 Day Avg. Volume3,069,625
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)17.61
Price to Sales (P/S)1446.46
P/FCF Ratio-6.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)£118.60M
Avacta Group plc Business Overview & Revenue Model
Company Description
Avacta Group plc is a biotechnology company based in the UK that focuses on developing innovative therapies and diagnostics for various diseases, including cancer. The company operates primarily in the life sciences sector, utilizing its proprieta...
How the Company Makes Money
Avacta Group plc generates revenue through multiple streams, including the sale of Affimer technology and related products to research institutions and pharmaceutical companies. The company also earns revenue by entering into collaborations and li...
Avacta Group plc Earnings Call Summary
Earnings Call Date:Sep 30, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 16, 2026
Earnings Call Sentiment Neutral
The earnings call reflects a company making significant progress in its clinical programs and preclinical data, with strategic collaborations enhancing market potential. However, financial constraints and the absence of secured partnerships pose challenges. Shareholder concerns regarding the share price remain unaddressed.Positive Updates
Clinical Program Progress
Avacta's lead program, faridoxorubicin (FAP-Dox or AVA6000), is advancing with promising preliminary data in salivary gland cancers. The company also anticipates dosing the first patient with FAP-exatecan in Q1 2026.
Negative Updates
Cash Position
Cash and cash equivalents decreased to GBP 12.65 million at the period end, compared to GBP 28.56 million for the same period in 2024.
Read all updates
Q2-2025 Updates
Positive
Negative
Clinical Program Progress
Avacta's lead program, faridoxorubicin (FAP-Dox or AVA6000), is advancing with promising preliminary data in salivary gland cancers. The company also anticipates dosing the first patient with FAP-exatecan in Q1 2026.
Read all positive updates
Company Guidance
During the Avacta Group plc Interim Results Investor Presentation, several key metrics were discussed regarding the company's clinical programs and financial status. The call highlighted Avacta's progress in its clinical stage programs, notably faridoxorubicin (FAP-Dox or AVA6000) and FAP-exatecan, with the former advancing to Phase Ib and the latter on track for its first patient dosing in Q1 2026. The company presented encouraging preliminary data for faridoxorubicin in salivary gland cancers and outlined plans for further data updates at ESMO 2025. Financially, Avacta reported cash and cash equivalents of GBP 12.65 million as of June 30, 2025, with cash outflows from operations at GBP 12.14 million for the first half of 2025. The management highlighted a renegotiation of the Heights Convertible Bond and a GBP 6.5 million gross fundraising to support quarterly bond payments. Additionally, Avacta anticipates releasing further data on its programs, including a pipeline update leveraging its pre|CISION platform, with an emphasis on strategic partnerships and business development to support its financial strategy and minimize shareholder dilution.Avacta Group plc Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.00K | 113.00K | 2.85M | 9.65M | 2.94M | 2.14M |
| Gross Profit | -682.00K | 113.00K | 2.84M | 4.23M | -2.50M | -973.00K |
| EBITDA | -12.03M | -17.62M | -14.12M | -34.78M | -26.69M | -16.40M |
| Net Income | -17.02M | -52.84M | -24.95M | -36.94M | -26.32M | -18.89M |
Balance Sheet | ||||||
| Total Assets | 29.24M | 48.27M | 73.19M | 92.65M | 47.00M | 67.46M |
| Cash, Cash Equivalents and Short-Term Investments | 12.64M | 12.87M | 16.63M | 41.78M | 26.19M | 47.91M |
| Total Debt | 20.40M | 22.93M | 23.51M | 62.94M | 1.70M | 2.04M |
| Total Liabilities | 29.09M | 38.99M | 51.39M | 74.21M | 5.78M | 5.53M |
| Stockholders Equity | 144.00K | 9.28M | 21.80M | 18.44M | 41.22M | 61.93M |
Cash Flow | ||||||
| Free Cash Flow | -13.55M | -23.94M | -16.13M | -17.03M | -21.82M | -12.31M |
| Operating Cash Flow | -13.51M | -23.60M | -14.87M | -16.43M | -20.51M | -10.64M |
| Investing Cash Flow | 8.77M | -1.43M | -9.00M | -25.04M | 18.70M | -21.90M |
| Financing Cash Flow | 666.00K | 26.09M | -1.30M | 56.90M | 232.00K | 51.65M |
Avacta Group plc Technical Analysis
Neutral
65.00
Price Trends
61.46
Positive
65.84
Negative
58.15
Positive
Market Momentum
1.52
Positive
48.54
Neutral
36.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AVCT, the sentiment is Neutral. The current price of 65 is below the 20-day moving average (MA) of 68.01, above the 50-day MA of 61.46, and above the 200-day MA of 58.15, indicating a neutral trend. The MACD of 1.52 indicates Positive momentum. The RSI at 48.54 is Neutral, neither overbought nor oversold. The STOCH value of 36.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:AVCT.
Avacta Group plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £119.34M | -4.45 | 90.29% | ― | ― | -94.12% | |
56 Neutral | £25.86M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
55 Neutral | £267.37M | -2.25 | 12.82% | ― | 1231.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | £285.19M | -1.74 | -361.23% | ― | ― | ― | |
42 Neutral | £4.70M | -5.98 | -153.80% | ― | ― | -616.67% | |
41 Neutral | £78.97M | -4.89 | -63.53% | ― | 198.49% | -26.66% |
* Healthcare Sector Average
GB:AVCT
Avacta Group plc
65.20
29.50
82.63%
GB:NFX
Nuformix Plc
0.18
0.09
93.55%
GB:PRTC
PureTech Health
110.00
-33.60
-23.40%
GB:SCLP
Scancell Holdings
11.50
3.60
45.57%
GB:4BB
4basebio UK Societas
510.00
-620.00
-54.87%
GB:AREC
Arecor Therapeutics PLC
68.50
25.00
57.47%
Avacta Group plc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Avacta Lifts Dosing Cap and Sets Path to Efficacy Trials for Faridoxorubicin
Positive
Feb 3, 2026
Avacta Therapeutics has reported two significant clinical milestones for its lead pre|CISION®-based drug candidate faridoxorubicin (AVA6000), including the removal of a historic maximum dosing limit tied to free doxorubicin exposure after Pha...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Avacta Wins FDA IND Clearance for Second pre|CISION® Cancer Drug AVA6103
Positive
Jan 21, 2026
Avacta Group plc has secured U.S. Food and Drug Administration clearance for its Investigational New Drug application for FAP-Exatecan (AVA6103), the company’s second pre|CISION® medicine and its first peptide drug conjugate using the p...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Avacta Advances Tumor-Targeted Oncology Pipeline and Extends Cash Runway Into Q3 2026
Positive
Jan 20, 2026
Avacta reported strong operational and RD progress in 2025, highlighting encouraging efficacy and safety data from its faridoxorubicin (AVA6000) Phase 1b expansion cohorts in salivary gland cancer and continued enrollment to refine trial design fo...
Business Operations and StrategyRegulatory Filings and Compliance
Avacta Names Strand Hanson as Nominated Adviser and Updates Share Capital and Governance Disclosures
Neutral
Jan 20, 2026
Avacta Group plc has appointed Strand Hanson Limited as its Nominated Adviser with immediate effect, a key governance and regulatory role for companies listed on AIM, and confirmed that its issued share capital stands at 440,415,495 ordinary share...
Business Operations and StrategyProduct-Related Announcements
Avacta Unveils Promising Data for Tumor-Targeted Cancer Therapy FAP-Exd
Positive
Dec 18, 2025
Avacta Group plc has released promising preclinical pharmacology data for FAP-Exd (AVA6103), a tumor-activated drug designed to deliver a highly potent topoisomerase I inhibitor directly to tumors. Key findings highlighted include enhanced tumor-s...
Business Operations and StrategyProduct-Related Announcements
Avacta’s Faridoxorubicin Shows Promising Results in Salivary Gland Cancer Trials
Positive
Dec 17, 2025
Avacta Group PLC announced promising Phase 1b clinical trial results for its drug faridoxorubicin (AVA6000) in treating salivary gland cancer (SGC), showing a 90% disease control rate across Phase 1a and 1b trials. The trial demonstrated clinicall...
Business Operations and StrategyProduct-Related Announcements
Avacta Group Announces Preliminary Data in Salivary Gland Cancer Trial
Positive
Dec 8, 2025
Avacta Group plc announced preliminary clinical data from its Phase 1b trial of Faridoxorubicin in patients with salivary gland cancer, with detailed results to be presented on December 17, 2025. This announcement marks a significant step in Avact...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.